Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with abdominal nodal disease had inferior lymphoma specific survival (p=0.04) and presented with higher age adjusted IPI (p<0.001), lactate dehydrogenase (p<0.001) and more often advanced stage (p<0.001), bulky disease (p<0.001), B-symptoms (p<0.001), and double expression of MYC and BCL2 (p=0.02) compared to patients without nodal abdominal involvement, but less often extranodal involvement (p<0.02).
|
31785002 |
2020 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, constitutive IP<sub>3</sub> signaling in lymphoma and leukemia cells is not only important for cancer cell survival, but also represents a vulnerability, rendering cancer cells dependent on Bcl-2 to limit IP<sub>3</sub>R activity.
|
29899382 |
2019 |
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, no associations were found between DAPK methylation and clinicopathological features of lymphoma, in relation to gender (OR = 1.07, 95% CI (0.72, 1.59), P = 0.751), age (OR = 1.01, 95% CI (0.66, 1.55), P = 0.974), international prognostic index (OR = 1.20, 95% CI (0.63, 2.27), P = 0.575), B symptoms (OR = 0.76, 95% CI (0.38, 1.51), P = 0.452), serum lactate dehydrogenase (OR = 1.13, 95% CI (0.62, 2.05), P = 0.683), and BCL-2 expression (OR = 1.55, 95% CI (0.91, 2.66), P = 0.106).
|
30682070 |
2019 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abbreviations: APC/C: Anaphase-Promoting Complex/Cyclosome; BAD: BCL2-Associated agonist of cell Death; BAK1: BCL2 Antagonist Kinase1; BAX: BCL2-Associated X; BCL2: B-cell Chronic Lymphocytic Leukaemia (CLL)/Lymphoma 2; BH: BCL2 Homology Domain; BID: BH3-Interacting domain Death agonist; BIM: BCL2-Interacting Mediator of cell death; BUB: Budding Uninhibited by Benzimidazoles; CDC: Cell Division Cycle; CDH1: Cadherin-1; CDK1: Cyclin-Dependent Kinase 1; CEP55: Centrosomal Protein (55 KDa): CIN: Chromosomal Instability; CTA: Cancer Testis Antigen; EGR1: Early Growth Response protein 1; ERK: Extracellular Signal-Regulated Kinase; ESCRT: Endosomal Sorting Complexes Required for Transport; GIN: Genomic Instability; MAD2: Mitotic Arrest Deficient 2; MCL1: Myeloid Cell Leukemia sequence 1; MPS1: Monopolar Spindle 1 Kinase; MYT1: MYelin Transcription factor 1; PLK1: Polo Like Kinase 1; PUMA: p53-Upregulated Mediator of Apoptosis; SAC: Spindle Assembly Checkpoint; TAA: Tumor-Associated Antigen.
|
30601084 |
2019 |
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We identified 122 patients diagnosed as having large B-cell lymphoma (44, MYC-negative; 29, MYC-EC; 23, MYC rearrangement; 22, MYC and BCL2 rearrangements; 4, MYC, BCL2, and BCL6 rearrangements). p53 expression significantly correlated with DLBCL with abnormal MYC status (MYC-EC, MYC rearrangement, and MYC overexpression), but adverse p53 prognostic effect was only seen with MYC-rearranged lymphoma.
|
30496802 |
2019 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
New targeted therapies for hematological malignancy include chimeric antigen receptor T cells (CAR T cells), Bi-specific T-cell Engager (BiTE) blinatumomab, and the antibody-drug conjugate (ADC) of calicheamicin inotuzumab ozogamicin for acute lymphoblasic leukemia (ALL) and lymphoma; the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib and phosphatidylinositol 3-kinase (PI3Kδ) inhibitor idelalisib for lymphoma and graft-versus-host disease (GVHD); FMS-like tyrosine kinase 3 (FLT3) inhibitors, such as midostaurin, sorafenib and gilteritinib for acute myeloid leukemia (AML); and the BCL-2 inhibitor venetoclax for a range of hematological malignancies including lymphoma and leukemia.
|
31688198 |
2019 |
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Notably, Rac1 expression, and its interaction with Bcl-2, positively correlate with S70pBcl-2 levels in patient-derived lymphoma tissues and with advanced stage lymphoma and melanoma.
|
31103719 |
2019 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that the survival of this type of lymphoma depends predominantly on BCL2 rather than on MCL1.
|
30523053 |
2019 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of the pro-survival member BCL-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukemia.
|
29732004 |
2018 |
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The mRNA and protein expression levels of B cell leukemia/lymphoma (Bcl‑2), Bcl‑2 associated X (Bax), cyclin dependent kinase 4 (CDK4), cyclin D1 and p21 were evaluated using reverse transcription‑polymerase chain reaction and western blot analysis, respectively.
|
29115462 |
2018 |
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Double-hit lymphoma (DHL) is defined as lymphoma with concurrent BCL2 and MYC translocations.
|
29310838 |
2018 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some cytokines and proteins associated with cell survival and proliferation, such as BAFF, APRIL, IL6 and BCL2, have been found to be elevated both in SLE and lymphoma.
|
30458319 |
2018 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mef2b<sup>D83V</sup> expression in mice leads to GC enlargement and lymphoma development, a phenotype that becomes fully penetrant in combination with BCL2 de-regulation, an event associated with human MEF2B mutations.
|
30205047 |
2018 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As bcl-2 proteins, cyclin dependent kinases (CDK) and phosphoinositol-3- kinase (PI3K) also influence mitochondrial physiology and metabolism with clear relevance to the pathogenesis of lymphoma, we investigated the potentiating effects of metformin when combined with novel agents Venetoclax (bcl-2 inhibitor), BAY-1143572 (CDK9 inhibitor) and Idelalisib (p110δ- PI3K inhibitor).
|
29765528 |
2018 |
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In order to gain a more comprehensive insight into the nature of venetoclax resistance mechanisms, we evaluated the changes in the BCL-2 family members at the genetic and expression levels in seven different venetoclax-resistant derived leukemia and lymphoma cell lines.
|
28578655 |
2017 |
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Functional Implications of the spectrum of BCL2 mutations in Lymphoma.
|
27543313 |
2017 |
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
|
27717585 |
2017 |
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, CCl4-induced apoptosis in the mouse liver was inhibited by hSAP, as measured by terminal-deoxynucleotidyl transferase mediated nick-end labeling (TUNEL) assay and cleaved caspase-3 expression. hSAP significantly restored the expression of B cell lymphoma/leukemia (Bcl)-2 and suppressed the expression of Bcl-2-associated X protein (Bax) in vivo.
|
28627620 |
2017 |
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There were 47 DTHLs, 36 cases with MYC and BCL2 and/or BCL6 extra signals (ES) and/or rearrangements (ES group, excludes DTHLs), 9 with MYC rearrangements only (single-hit lymphoma), and 95 with no MYC abnormalities (NM).
|
28614202 |
2017 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, the histiocytic tumor component has been shown to harbor BCL2 gene translocations that are identical to those found in the lymphoma.
|
27134111 |
2016 |
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lymphoma viability remained unaffected by the genetic deletion or pharmacological inhibition of all alternative BCL-2 family members.
|
27055871 |
2016 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A distinctive form of diffuse large B-cell lymphoma is the double-hit lymphoma, with most cases exhibiting a combined MYC and BCL2 rearrangement, leading some hematopathologists to propose the term MYC/BCL2 lymphoma.
|
27391453 |
2016 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
He trained in oncology at St Bartholomew's Hospital, London, where he was an Imperial Cancer Research Fund (ICRF) Clinical Research Fellow and completed his doctoral research on the Bcl-2 gene, its potential as a therapeutic target in lymphoma and the effects of CD40 ligation on the B-cell surface.
|
26616222 |
2016 |
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-apoptotic BCL-2 is classified as an oncogene, as damage to the BCL-2 gene has been shown to cause a number of cancers, including lymphoma.
|
27043233 |
2016 |
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Most of the refractory patients exhibit double-hit lymphoma (MYC-BCL2 rearrangement) or double-protein-expression lymphoma (MYC-BCL2 hyperexpression) which have a more aggressive clinical picture.
|
27913503 |
2016 |